In human epilepsy patients with FCD type II with identified causal mutation in the mTOR pathway, the frequency of the alternative allele has been repeatedly reported as typically between 1 and 15% [7, 59, 60]. The gene discussed is MTOR; the disease is isolated focal cortical dysplasia type II.